Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
News
AlzeCure’s neuropathic pain candidate study reaches crucial phase
Research concerns ACD440 – a non-opioid drug which treats peripheral neuropathic pain
Medicines policy may be halting Government’s drive for growth
Lilly is calling for Government to freeze the statutory scheme repayment rate for 2023
Milestone product launch for Kelso Pharma
Acepiro tablets for respiratory diseases will be available across the UK prescription market
Orbsen announces results from Nephstrom trial
Clinical study is researching patients with diabetes and advanced chronic kidney disease
NICE recommends Alexion’s asfotase alfa across England
Therapy involves patients with paediatric-onset hypophosphatasia – a rare bone disease
Netris Pharma starts hepatocellular carcinoma study
Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev
Gilead’s CAR T-cell therapy recommended for use across the NHS
Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Storm reveals STC-15 data for patients with acute myeloid leukaemia
Data shows that STC-15 exhibits efficacy as a single agent and in combination with venetoclax
Evgen completes three cohorts for SFX-01
New enteric-coated tablet formulation will now replace the previous prototype capsule
First-in-human implants for Amber Therapeutics’ bioelectrical therapy
Amber-UI presents a significant opportunity to treat urge and mixed urinary incontinence
Memo Therapeutics reveals positive AntiBKV data
Therapy involves renal transplant patients requiring treatment of BK polyomavirus infection
First patients enrolled for Priothera’s mocravimod trial
Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia
OxSonics trial produces positive SonoTran data
During the research SonoTran is being evaluated in patients with metastatic colorectal cancer
NICE recommends Takeda’s Ninlaro triplet regimen
Therapy involves patients living with relapsed or refractory multiple myeloma
